Black man living with HIV in USA holding a rainbow umbrella

ENDING HIV

We are the only pharmaceutical company solely focused on combating, preventing, and ultimately eradicating HIV and AIDS, but of course, none of what we do can be achieved alone – we believe in the power of partnership.

We partner in research, in access and with the community because we believe that we are stronger together when it comes to working towards the UN target of ending the AIDS epidemic by 2030.

Of the 38 million people living with HIV globally, almost 75% live in low- and middle- income countries, and 27% are not on treatment.

We are committed to enabling access to our medicines to benefit people affected by HIV, regardless of their income, location, status, age or gender.  

Despite advances in prevention, treatment and care, people living with HIV continue to face unique challenges that impact their quality of life daily. HIV stigma continues to persist, affecting those living with the virus as well as their support networks.

Despite progress, paediatric HIV remains a global issue, with children disproportionately affected by the HIV epidemic.

Latest statistics show there are 1.7m children under 15 years of age living with HIV, with only half having access to treatment. 

We support a growing community of researchers, policy makers, community organisations, advocates and other stakeholders who are interested in studying current HIV care practices.

Our aim is to challenge the status quo, and shape health policy and practices that can lead to an HIV-free future. 

OUR STORIES: SCIENCE AND INNOVATION

View all stories

To lift the substantial burdens of daily treatment and social stigma associated with HIV, a cure is essential towards accomplishing our goal of ending the HIV epidemic. With this goal in mind, we are in pursuit of a cure for HIV. 

We’ve got more than 50 active collaborations worldwide with pharmaceutical and biotechnology companies, government agencies, academic institutions and not-for-profit organisations to broaden our capabilities and enhance our performance. 

With significant progress made in the fight against HIV, how do we make sure that clinically proven tools are implemented into real-world settings?

NP-GBL-HVX-COCO-220017 November 2021.